Eisai to Divest Rights to 2 CNS Drugs to UK’s CNX in France, Algeria

April 4, 2024
Eisai said on April 2 that it has agreed with London-based CNX Therapeutics to transfer its marketing rights in France, the French overseas territories, and Algeria for two CNS medicines. As per the deal, the Japanese company will now move...read more